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The inflammatory response is a well-established part of, and a prerequisite for, venous
thrombosis. To better understand the pathophysiology of venous thrombosis and to
identify improved diagnostic biomarkers, further studies of the relationship between
inflammation and coagulation are needed. We review previous studies concerning
inflammatory biomarkers in venous thromboembolism, in particular cytokines, soluble
adhesion molecules and matrix metalloproteases as predisposing, diagnostic and
prognostic factors in venous thrombosis. Elevated cytokines and genetic alterations
coding for cytokines are found in several patient cohorts which indicate that cytokines
are involved as predisposing factors in venous thrombosis development. Increased
levels of pro-inflammatory cytokines are detected both in animal models and in
patients with acute venous thrombosis and clinical trials, although currently without
evident diagnostic value. Adhesion molecules are crucial in the development of venous
thrombosis, especially P-selectin seems important in initiating leukocyte accumulation
and adhesion to endothelium for subsequent platelet accumulation. Several studies have
demonstrated increased soluble P-selectin levels in patients with venous thrombosis,
emphasizing its potential role as diagnostic marker and also as a therapeutic target.
Matrix metalloproteases are essential effectors during venous thrombosis resolution and
may impact vessel wall fibrosis, and together with their natural occurring inhibitors are
crucial in acute and chronic thrombosis pathophysiology. Furthermore, studies in animal
models of venous thrombosis have demonstrated anti-inflammatory treatment to be
effective in terms of thrombus resolution and reduction of vessel wall damage, without
increase in bleeding risk during the course of treatment. Thus, soluble mediators should
be further investigated both as possible biomarkers and therapeutic targets in venous
thromboembolic disease.
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INTRODUCTION
Venous thromboembolism (VTE) is one of the most common
haematological conditions, associated with increased morbidity
and mortality, accounting for over 500,000 deaths per year in
the European Union (1). Deep vein thrombosis (DVT) and
pulmonary embolism (PE) could be difficult to diagnose, with
undiagnosed VTE therefore representing an increased risk of
death (1, 2). Improved risk stratification and diagnostic tools are
important measures for VTE treatment and prevention (3).
Established risk factors for VTE include familial
thrombophilia and acquired factors such as malignancies,
previous VTE, reduced mobility, trauma or surgery, old age,
pregnancy, heart failure, myocardial infarction, ischaemic stroke,
obesity and use of oral contraceptives (4–6). Several of these
risk factors represent inflammatory conditions (7). Emerging
evidence suggests infection as a more important risk factor for
VTE than previously recognized, and the coagulation systemmay
play a major role in immune defence (8, 9). To better understand
the pathophysiology of VTE and to identify improved diagnostic
biomarkers for venous thrombosis, further studies on the
relationship between inflammation and coagulation are needed
(10). The term inflammation, derived from the Latin word
inflammatio, is defined as a complex biological response of body
tissues to harmful stimuli such as pathogens, damaged cells
or irritants (9, 11–13). It is regarded as a protective response
involving the innate and adaptive immune system, various
blood cells, vessel wall, and a wide range of molecular mediators
derived from the various cells involved in the inflammatory
process. The main role of inflammation is to eliminate the initial
cause of cell injury, to mediate clearance of necrotic cells and
damaged tissues from the original insult and inflammatory
process, and to initiate tissue repair. The classical local signs
of inflammation are redness, heat, swelling, pain, and loss of
function. In addition, severe inflammation also elicits systemic
effects, probably mediated, at least in part, by circulating soluble
mediators originating from the local inflammatory process.
The triad of increased coagluability, blood flow disturbance
and vessel wall changes was postulated already by Rudolf Virchow
(1821–1902) (14). However, increasing knowledge regarding the
biological process bridging inflammation and coagulation have
been established since Virchow’s initial postulate. In this review
we seek to further discuss the complex relationship between
inflammation and VTE.
PATHOPHYSIOLOGY OF VTE
Endothelial cells are key regulators of the inflammatory response,
as they: (i) form a physical barrier for blood cells and regulate
the vascular permeability for immune cells, soluble proteins,
electrolytes, and water; (ii) regulate the intravascular coagulation;
(iii) regulate the vascular tone and blood pressure through
initiation of vasoconstriction/vasodilatation; and finally (iv)
release hormones and other soluble mediators, such as cytokines,
that initiate and regulate the inflammatory process (15).
Endothelial cells activate, control, and direct leukocytes
mainly through their cell surface expression of adhesion
molecules and the release of chemotactic chemokines after
activation. This enables immunocompetent cells to adhere
to the endothelial cells and consequently cross the vessel
wall by transendothelial migration (TEM), thus resulting in
accumulation of immunocompetent cells at the inflammation
site (16). Rapid endothelial activation (i.e., within minutes)
is induced by stimuli like histamine and platelet-activating
factor (PAF), initiating the expression of preformed adhesion
molecules. In contrast, pro-inflammatory cytokines, such as
interleukin (IL)-1β and Tumour Necrosis Factor (TNF)-α,
induce a slower endothelial activation (i.e., within hours),
involving transcriptional activation of adhering molecules and
chemoattractants (16). The pathogenesis of VTE differs from
that of arterial thrombosis, as venous thrombosis is initiated
by intravascular events without exposure of the subendothelial
structures (17). In amurinemodel of DVT inflamed endothelium
increased the expression of a wide range of adhesion molecules
that attach neutrophils and monocytes to the vessel wall, as an
initial step in the formation of thrombus mainly consisting of
leukocytes and few platelets (18). A complex interplay between
monocytes, neutrophils, platelets, and the coagulation cascade
leads to the formation of a thrombin-rich thrombus. Activated
monocytes express TF that initiates the extrinsic pathway of the
coagulation cascade. Thus, findings from the study suggest that
TF expression by monocytes appears to be more important than
endothelial expression of TF in triggering the coagulation cascade
in DVT.
Both the leukocyte-endothelium and leukocyte-platelet
interaction is a prerequisite for thrombosis initiation, shown in
mouse-model studies of leukocyte integrin Mac-1, platelet C-
type lectin-like receptor (CLEC-2), and vWF (19–21). Leukocyte
integrin Mac-1 mediates adhesion of leukocytes-endothelium via
the intracellular adhesion molecule-1 (ICAM-1), and adhesion of
platelets via GPIbα, and targeting this adhesion-molecule could
represent a possible therapeutic target (21). CLEC-2 is a receptor
for podoplanin released from the endothelium during venous
stenosis, and subsequently trigger thrombosis formation (20).
CLEC-2 deficient mice are protected against thrombosis, and
treatment of anti-podoplanin neutralizing antibodies reduces
thrombosis size in animal models.
Moreover, neutropenia, genetic knockout of factor XII, and
neutrophil extracellular traps (NETs) disintegration protected
against the formation of DVT (22). This indicating neutrophil
activation as a prerequisite for DVT formation, since neutrophils
bind coagulation factor XII and release NETs, which together
with platelets activate the coagulation cascade both through the
intrinsic and extrinsic pathways (18). The host might prevent
vascular occlusion through DNases that helps dissolve the NETs




Cytokines, adhesion molecules, and matrix metalloproteases
(MMPs) are some of the key components involved in
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FIGURE 1 | The figure present the main interactions between cytokines, chemokines, adhesion molecules, matric metalloproteases (MMPs), and coagulation
activation involved in the pathophysiology during venous thrombosis development. Cytokines are early initiators of inflammation, ameliorating the interactions between
leukocytes and endothelial cells. Activated leukocytes and endothelial cells express adhesion molecules which promotes leukocyte attachment to the endothelium
which is important in the initiation and development of venous thrombosis. MMPs are involved in fibrosis of the vein walls modulation. In addition MMPs are important
modulators of cytokines and adhesion molecules during inflammation as they can alter cytokines and contribute to adhesion molecule shedding.
inflammation, see Figure 1 (12, 16, 24). Cytokines are important
for cell-cell communication during inflammation, and they
are highly heterogeneous and can be classified based on their
function, structure, or based on their mechanism of action in
the immune system, i.e., pro-inflammatory, anti-inflammatory
or adaptive (12). The main pro-inflammatory cytokines belong
to the IL-1, IL-6, IL-17, interferon, and TNF families. The
IL-1 family is essential for initiation of the inflammatory
cascade (25, 26), and cytokines in the IL-6 family have both
immunoregulatory, as well as other systemic effects (27). The
main anti-inflammatory cytokines include those in the IL-10 (28)
and IL-12 families (29–32).
Adhesion molecules are important mediators of cellular
adhesion between leukocytes and endothelial cells and can
exist in the membrane-bound as well as the biologically active
soluble forms (16). The adhesion molecule family includes
selectins (L-, E-, and P-selectins) and various immunoglobulin
(Ig) family members [e.g., Vascular Cell Adhesion Molecule 1
(VCAM-1), ICAM-1/2]. E-selectin is expressed by endothelial
cells, L-selectin by leukocytes, and P-selectin by endothelial cells
and platelets, and they are all induced by pro-inflammatory
mediators. Selectins are important for leukocyte rolling, and P-
selectin is also involved in thrombus formation and intravascular
coagulation during infection (9, 16). Ig family members are of
particular importance in firm adhesion and trans-endothelial
migration of leukocytes, and both ICAM-1 and VCAM-1 are
expressed by endothelial cells (33).
Finally, MMPs have emerged not only as molecules involved
in modelling extracellular tissue, but also as important regulators
of inflammatory responses, e.g., through their activation
and modulation of pro-inflammatory cytokines (24). Matrix
metalloproteases (MMPs) and protease inhibitors both interact
with cytokines and adhesion molecules at various levels. Hence,
one may argue that these mediators should be regarded as
functional parts of the cytokine network. MMPs are zinc-
dependent enzymes belonging to the metzincin superfamily
of zinc endopeptidases that, to date, comprise 24 mammalian
proteases (24, 34, 35).
CYTOKINES AND VTE
A range of risk factors for VTE include inflammatory conditions,
gives rise to the hypothesis that elevated inflammatory mediators
are risk factors for DVT and post thrombotic syndrome (PTS).
Levels of several cytokines are found elevated as part of VTE
pathobiology (Table 1), and findings from selected human and
animal studies showing the importance of adhesion molecules in
VTE are presented in Table 1.
Cytokines in Inflammation and
Predisposition to VTE
Single nucleotide polymorphisms (SNPs) affecting cytokine genes
are associated with an increased risk, and others with a reduced
risk, of VTE (Table 1) (4, 36, 39, 40, 67). IL-1 cytokines are early
inflammatory mediators. SNPs in IL-1α and IL-1β have shown
to be associated with reduced risk of DVT, while another SNP
for IL-1β is associated with increased risk of DVT (38). IL-6 is
an inflammatory mediator later in the cascade, and is maybe the
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TABLE 1 | Cytokines as predisposing factors, diagnostic markers, and prognostic markers in venous thrombosis.
Predisposing factor Acute reaction and diagnostic use Effect on thrombus resolution
IL-1α −899C/T ↓ SNP: 108 DVT vs. 325 controls (36)
IL-1β rs1143634 ↓ SNP in DVT in larger cohort (4)
↔ 506 DVT vs. 1464 controls (37)
IL1RN-H5H5 ↑ Leiden thrombophilia study (38)
IL-4 −589T allele ↑ SNP: 108 DVT vs. 325 controls (36)
IL-6 ↔ 506 DVT vs. 1464 controls (37)
−174 CC ↑ SNP: 108 VTE vs. 325 controls (36)
−174G > C ↑ SNP: 130 DVT+ and 190 DVT−
(cancer patients) vs. 215 controls (39)
−174 GC ↑ SNP: 119 VTE vs. 126 controls (40)
−174G > C ↔ SNP: 128 DVT, 105 PE vs. 122
controls ↔ IL6: 128 DVT, 105 PE vs. 122 controls
(41)
CC −572 G/C ↑ 140/246 VTE vs. 160/292 controls,
respectively (42, 43)
↑IL6, 200 ovarian cancer, predictor for VTE (44)
↑IL6 in 34 VTE 322 patients with diffuse large B-cell
lymphoma (45)
−174G > C ↔ 128 DVT, 105 PE vs. 122
controls (41)
↑ 84 VTE vs. 100 controls (46)
↑ 49 VTE vs 48 controls (47)
↑ 40 DVT+ vs. 33 DVT− (7)
↑ 201 DVT vs. 60 controls (48)
↑ abdominal cancer, post-operative [40 DVT
vs. 40 non-DVT vs. 40 controls (49)
↔ 181 cases vs. 313 controls (50)
↑ 68 cases vs. 67 controls (51)
↑ 182 recurrent VTE vs. 350 controls (52)
↑ in post-thrombotic syndrome, 49 DVT (53)
↑ in post-thrombotic syndrome, 136 DVT
(mice) (54)
↑ in post-thrombotic syndrome, 387 DVT (55)
↑ risk for post-thrombotic syndrome, 110 DVT
patients (56)
↑ 201 DVT vs. 60 controls (48)
↔ 181 cases vs. 313 controls (50)
↑43 DVT vs. 43 controls (57)
↑ increased risk for post-thrombotic syndrome,
803 participants SOX trial (58)
CXCL8/IL-8 ↔ 506 VTE vs. 1464 controls (37)
−251AT ↑ SNP: 119 VTE vs. 126 controls (40)
↑ 474 DVT vs. 474 controls (59)
↑ 49 VTE vs. 48 controls (47)
↑ 40 DVT+ vs. 33 DVT− (7)
↔ 181 cases vs. 313 controls (50)
↑ 182 recurrent VTE vs. 350 controls (52, 59)
↔ 181 cases vs. 313 controls (50)
↑43 DVT vs. 43 controls (57)
correlation between baseline lumen diameter of
the femoral thrombi and IL-8 cytokine (60)
↔ risk for post-thrombotic syndrome, 387 DVT
(55)
IL-10 ↓ in VTE group in trauma cohort (61)
↔ 506 VTE vs. 1464 controls (37)
rs1800872 ↑ SNP IL-10 in DVT cohort (22 413
women) (4)
−1082GG genotype ↓ in 660 DVT vs. 660 controls
(62)
↑IL10 in 34 VTE 322 patients with diffuse large
B-cell lymphoma (45)
↓ abdominal cancer, post-operative (40 DVT
vs. 40 non-DVT vs. 40 controls (49)
↔ 181 cases vs. 313 controls (50)
↔ 181 cases vs. 313 controls (50)
↓ 43 DVT vs. 43 controls (57)
↑ increased risk for post-thrombotic syndrome,
803 participants SOX trial (58)
↔ risk for post-thrombotic syndrome, 387 DVT
(55)
IL-12p70 ↔ 506 VTE vs. 1464 controls (37)
IL-13 ↑ TT genotype: 108 VTE vs. 325 controls (female)
(36)
CCL2/MCP-1 −2518AG ↑ SNP: 119 VTE vs. 126 controls (40) ↔ 181 cases vs. 313 controls (50) ↑ 182 recurrent VTE vs. 350 controls (52)
↑ in post-thrombotic syndrome, 136 DVT
(mice) (54)
↔ 181 cases vs. 313 controls (50)
↔ risk for post-thrombotic syndrome, 387 DVT
(55).
TNF-α ↑ TNF-α in VTE in cancer cohort (63)
↑ TNF-α and TNFA haplotype in 15 VTE in cancer
cohort 157 GI cancer and controls 157 (64)
↑−308A allele 68 patients vs. 62 controls (65)
↔ 49 VTE vs. 48 controls (47)
↑ 201 DVT vs. 60 controls (48)
↑ 68 patients vs. 67 controls (51)
↑43 DVT vs. 43 controls (57)
IFN-γ ↑ IFN-γ enhances thrombus resolution in mice
through enhanced MMP9 and VEGF
expression in mice (66)
TNFSF4 SNP ↑ (921C > T), ↓ (rs3850641) 344 DVT vs.
2269 controls (67)
(Continued)
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TABLE 1 | Continued
Predisposing factor Acute reaction and diagnostic use Effect on thrombus resolution
NF-κB ↑ abdominal cancer, post-operative (40 DVT
vs. 40 non-DVT vs. 40 controls (49)
TGF-β1
TGF-β2
↔ 181 cases vs. 313 controls (50) ↔ 181 cases vs. 313 controls (50)
↓ MATS 42 recurrent DVT vs. 84 controls (68)
PDGF ↔ 181 cases vs. 313 controls (50) ↔ 181 cases vs. 313 controls (50)
Multiplex
analysis
IL1RA, EGF, HGF CXCL5, CXCL10, and Leptin
↑21 DVT vs. 20 controls (69)
IL1-α, IL1-β, IL-2, IL-4, IL-5, IL-6, IL-7,
IL-8/CXCL-8, IL-10, IL-12, IL-13, IL-17, IL-22,
IL1RA, CCL-3/4/5/11, CXCL-5/10/11, bFGF,
G-CSF, GM-CSF, VEGF, TPO, EGF, HGF, and
Leptin, IFN-γ CD40L, TNF-α ↔21 DVT vs. 20
controls (69).
This table summarizes selected key human and animal studies of c response in venous thrombosis. Arrows indicate the following: the cytokine/genetic polymorphism coding for the
cytokine is elevated/more frequent (↑), decreased/less frequent (↓), or unchanged (↔) in DVT cohorts as a predisposing factor (left column), as part of the acute reaction (middle
column), or as a risk factor for post-thrombotic syndrome or recurrent DVT (right column). PTS, post thrombotic syndrome; SNP, single nucleotide polymorphism; TIMP, tissue inhibitor
of metalloproteases. Control, healthy control.
most studied cytokine during inflammation. Also certain SNPs of
IL-6 has been associated as a risk factor for VTE (36).
A number of small case-control studies demonstrated
increased levels of pro-inflammatory, or decreased levels of anti-
inflammatory, cytokines in patients at risk for DVT (45, 61, 63).
Although in a larger, prospective population-based case-control
study, no such associations were found (37).
Increased inflammation is also a common feature of most
of the epidemiologically proven risk factors (70). As previously
genetic factors affecting the coagulation system (e.g., factor
V, Leiden, and prothrombin mutations) are predisposing risk
factors for VTE (4, 41, 71, 72). However, family history in itself is
an independent risk factor that could be more useful than genetic
testing when assessing the risk for thrombosis (73). This indicates
that genetic predispositions are multifactorial and a complex
combinations of several genetic traits, in which inflammation
could represent a part of the explanation.
Cytokines as Part of the Acute Reaction
and Their Possible Diagnostic Use
Increased levels of pro-inflammatory cytokines were detected
in animal models of acute venous thrombosis (74). Several
inflammatory cytokines like IL-6, IL-8/CXCL-8, and TNF-α are
increased during acute thrombosis, although with no evident
diagnostic value (7, 40, 46, 47, 49, 59). The focus of most of
the studies has been the main cytokines IL-1, IL-6, IL-8/CXCL-8,
and IL-10. Increased inflammatory mediators during the clinical
course of thrombosis are in line with clinical signs as redness
and swelling. However, even broader inflammatory profiles have
limited diagnostic value as most differential diagnoses also show
extensive inflammatory activity (69).
Cytokines and Thrombus Resolution
Inflammation is considered as an essential response during
venous thrombosis formation and resolution, and increased
levels of inflammatory cytokines seem to have prognostic impact
(53, 55, 56). IL-6 could represent a therapeutic target in the
prevention of post-thrombotic syndrome, as suggested by a
previous study using an animal model of DVT (54).
In conclusion, cytokines and play a role as predisposing
factors for VTE, however they are not established as important
risk factors. Elevated cytokines are found in several studies of
VTE patients, although it is difficult to draw clear conclusion
of causality of the cytokines role in venous thrombosis in these
patient cohorts.
ADHESION MOLECULES AND VTE
Adhesion molecules are part of the formation of the
inflammatory response (Figure 1). The P-selectin stored in
platelets and endothelial cells, has been proposed as a key
molecule in thrombosis and haemostasis (75, 76). P-selectin has
been found upregulated as early as 6 h after thrombus induction
(77). The binding of P-selectin to its receptor P-selectin ligand-
1(PSGL-1) present on the surface of leukocytes and platelets,
initiates pro-coagulatory mechanisms (77, 78). Findings from
selected human and animal studies showing the importance of
adhesion molecules in DVT are presented in Table 2.
Predisposing Factors for VTE
The gene for coagulation factor V is genetically closely linked
to the genes encoding the selectins. In a study by Uitte de
Willge et al. examination of the haplotypes of E-selectin and P-
selectin demonstrated no association with DVT risk (79). Proctor
et al. observed that serum P-selectin (sP-selectin) and IL-10 had
a consistent association, during the first week after an injury,
with the presence or absence of VTE. The sP-selectin level
difference was not statistically significant between the groups.
Those patients who developed VTE had a higher sP/IL-10 ratio,
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TABLE 2 | Adhesion molecules as predisposing factors, diagnostic markers and prognostic markers in venous thrombosis.
Predisposing factor Acute reaction and diagnostic use Effect on thrombus resolution
P-selectin ↔ in DVT group in trauma cohort (61)
↔ selectin haplotypes in Leiden Thrombophilia
Study (79)
↑, meta-analysis 586 DVT, 1,843 controls (75)
↑, lower extremity: 112 DVT vs. 122 non-DVT
↔, upper extremity: 32 DVT vs. 13 non-DVT (76)
↑ 62 DVT vs. 116 non-DVT (78)
↑ in DVT patients vs. controls (80)
↑ 49 VTE vs. 48 controls (47)
↑ 22 DVT vs. 21 non-DVT vs. 30 controls (81)
↔ 37 DVT vs. 32 non-DVT (82)
↑ 52 DVT vs. 83 non-DVT (83)
↑ platelet expressing P-selectin in post-operative
DVT (84)
↑ 89 DVT vs. 126 controls (85)
↑21 DVT vs. 68 non-DVT (69)
↑ in acute DVT predicts post-thrombotic
syndrome, 49 DVT (53)
↑ After anticoagulation therapy, possible
therapeutic target? (86)
↓ 1 month after DVT: patients with chronic
thrombosis vs. in patients with resolved (80)
P-selectin inhibition decreases post-thrombotic
vein wall fibrosis in a rat model (87)
P-selectin inhibition enhances thrombus
resolution and decreases vein wall fibrosis in a
rat model (88)
P-selectin/PSGL inhibitors equal enoxaparin in
VTE treatment (77)
ICAM-1 ↔ ICAM-1 37 DVT vs. 32 non-DVT (82)
↑ 181 cases vs. 313 controls (50)
↔21 DVT vs. 20 controls (69)
↑ risk for post-thrombotic syndrome, 387 DVT
(55)
↑ increased risk for post-thrombotic syndrome,
803 participants SOX trial (58)
VCAM-1 ↔ 49 VTE vs. 48 healthy controls (47)
↔ 37 DVT vs. 32 non-DVT (82)
↑ 52 DVT vs. 83 non-DVT (83)
↑ 181 cases vs. 313 controls (50)
↑21 DVT vs. 68 non-DVT 20 controls (69)
↔ risk for post-thrombotic syndrome, 387 DVT
(55)
↑ 181 cases vs. 313 controls (50)
E-selectin ↔ selectin haplotypes in Leiden Thrombophilia
Study (79)
↔ 37 VTE vs. 32 non-VTE (82)
↑ abdominal cancer, post-operative [40 DVT vs. 40
non-DVT vs. 40 controls] (49)
↔ 28 VTE vs. 92 non-VTE (89)
This table summarizes selected key human and animal studies of adhesion molecule response in venous thrombosis. Arrows indicate the following: the adhesion molecule/genetic
polymorphism coding for the cytokine is elevated/more frequent (↑), decreased/less frequent (↓), or unchanged (↔) in DVT cohorts as a predisposing factor (left column), as part of the
acute reaction (middle column), or as a risk factor for post-thrombotic syndrome or recurrent DVT (right column). PTS, post thrombotic syndrome; SNP, single nucleotide polymorphism;
TIMP, tissue inhibitor of metalloproteases. Control, healthy control.
where lower levels of IL-10 accounted for the ratio-difference,
statistically significant to those without VTE (61).
The Acute Phase Reaction and Diagnostic
Use
Currently the biomarker used in VTE diagnostic is D-dimer,
which is a non-specific biomarker of VTE, being a fibrin
degradation product (76). sP-selectin has been a candidate as
replacement of D-dimer as a diagnostic marker. An early study
published in 2000 demonstrated increased sP-selectin levels
in thrombosis patients (85). The two most promising studies
demonstrated high positive predicative value (PPV) of 91/100%,
and a specificity of 97.5/96% for establishing the diagnosis of
DVT, with Wells score ≥ and sP-selectin ≥90 ng/ml (76, 78).
The first study suggested that P-selectin may be both more
specific and sensitive thanD-dimer as a diagnostic marker at least
in specific subsets of patients (78). The subsequent study also
demonstrated higher specificity for sP-selectin, however D-dimer
in combination withWell’s score performed as well as sP-selectin
combined with Well’s score in ruling out DVT (76).
Changes in platelet expression of P-selectin may also be used
as a diagnostic marker of susceptibility to DVT in high risk
surgical procedures, demonstrated in a study of female patients
undergoing a total knee arthroplasty (84). A small prospective
study published in 2003 examined ICAM-1, VCAM-1, E-selectin,
and P-selectin in the diagnostic of DVT, and no significant
difference were found between the concentrations in patients
with DVT vs. controls (82). Increased levels of E-selectin have
also been found as an independent risk factor associated DVT
in postoperative patients with abdominal malignancy (49), and
VCAM levels seem to be higher in DVT patients (83).
Adhesion Molecules and Thrombus
Resolution
Post-deep vein thrombosis venous insufficiency is characterized
by vein wall fibrosis, and is central in the development of PTS,
where the long term outcome is influenced by early resolution
of the thrombus (80). The inflammatory response has been
found to affect both thrombus resolution and PTS development
(55, 77, 87). P-selectin and D-dimer have been found elevated in
the acute phase of DVT, and decrease significantly during the first
month (86). The recanalization is inversely related to coagulation
markers and fibrinolytic inhibition (53). Increased levels of
P-selectin may represent a hypercoagulable state, although it
remains unclear if it precedes and promotes thrombosis or is a
consequence of thrombosis (86). In patients with a more serve
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inflammatory response, the endogenic fibrinolysis is inhibited
and coagulation stimulated and therefore thrombus resolution is
delayed. This is demonstrated by an increased level of IL-6 and P-
selectin in the chronic phase, indicating a worse prognosis (53).
However, sP-selectin levels are higher 1 month after a thrombosis
in patients who resolved their DVT, implying a more active
thrombus metabolism in these patients compared to those with
chronic thrombosis (80).
A cross-sectional study in a chronic phase after pregnancy-
related DVT demonstrated higher levels of ICAM-1 and VCAM-
1 in cases compared to controls. However, after univariate
analyses these markers where not significantly associated with
PTS (50). Though, patients who develop PTS appear to have
higher ICAM-1 level then those patients who do not develop PTS
(55).
P-selectin is strongly influenced by treatment of oral
anticoagulation, illustrated by increased levels within fewmonths
after discontinuation of vitamin-K antagonists. Two rodent
model studies showed that P-selectin inhibition decreases post
DVT vein wall fibrosis (87, 88). It is assumed that the effect
is associated with decreased profibrotic mediators, independent
of changes in thrombus masses (87). A meta-analysis of non-
human primate models confirmed a significant difference in the
effect of vein-reopening and inflammation when comparing P-
selectin antagonism and saline (78). Observations that thrombus
formation and extension may be inhibited, and enhanced
resolution when a DVT is treated with P-selectin antagonists
highlight the importance of sP-selectin in thrombosis (75, 88).
In conclusion, adhesion molecules are vital for thrombus
formation. P-selectin is a possible diagnostic marker for DVT,
and might also represent a therapeutic target.
MATRIX METALLOPROTEASES AND VTE
MMPs are important in inflammatory responses through
their regulation of inflammatory mediators, as well as in
maintenance of the function and integrity of physical barriers
(Figure 1) (24). Animal models have suggested that MMPs are
important effectors during VTE resolution and reduce vessel wall
fibrosis (66, 90), thus indicating that MMPs represent potential
therapeutic targets (54). Findings from selected human and
animal studies showing the importance of MMPs in DVT are
presented in Table 3.
The Role of MMPs as Predisposing Factors
for VTE
SNPs affecting MMP-9 and IL-6 have been evaluated as
predisposing factors for DVT in cancer patients (39). When
comparing healthy controls with cancer patients with DVT, both
SNPs were associated to DVT. Distribution of the SNPs was
similar between healthy controls and DVT negative cancer cases.
The results indicate that the GG and CC genotypes, respectively
for both SNPs, are associated with increased risk of DVT in
cancer patients by inducing the release of IL-6 with subsequent
increment of MMP-9.
MMPs in Acute VTE and Post Thrombotic
Syndrome
Studying PTS, one study aimed to quantify the change in vein
wall thickness in patients who failed to resolve DVT within
6 months, and whether differences in levels of inflammatory
proteins associated with venous remodelling (80). Results
demonstrated increased levels of MMP-9 antigen in thrombosed
patients compared with controls. Other biomarkers such as D-
dimer and P-selectin were higher in thrombosed patients at
diagnosis, although not significantly different at 6 months. P-
selectin gene expression were higher in leukocytes from patients
with chronic DVT compared with those who resolved within 1
month after diagnosis.
In another study the expression of inflammatory biomarkers
in the early phase of DVT and their correlation with the onset
of PTS was evaluated (48). Samples were harvested from 201
patients after their first episode of DVT over a period for
18 months, and from 60 patients without DVT. Analyses of
inflammatory biomarkers demonstrated high plasma levels of
MMPs and cytokines during the acute phase after DVT. Patients
with PTS demonstrated higher levels of MMP-1 and MMP-8
than patients without PTS, implying a close relationship between
DVT, the individual risk of PTS and specific biomarkers such as
MMPs.
In conclusion, few studies exploring the role of MMPs in
VTE are performed. MMPs are elevated during VTE and PTS,
although also during other inflammatory conditions, and so far
not proven value as diagnostic markers (69).
CONCLUSIONS AND FUTURE
PERSPECTIVE
Inflammatory mediators are part of several cascades in the
pathophysiology of VTE; predisposing factors, initiation and
prolongation of acute thrombosis and resolution. Especially
cytokines have been implicated as a predisposing factor in several
studies, while adhesion molecules and MMPs are to a lesser
degree studied (Tables 1–3). High quality studies demonstrating
the effect of inflammatory mediators as predisposing factors
of thrombosis are difficult to design. However, the performed
studies combined with the knowledge that most risk factors
of VTE involves inflammation, indicate an important role of
inflammatory mediators as risk factors for thrombosis. The
complexity of the genetic predisposition of most human disease
hampers to decipher the exact impact of different genetic
and environmental factors (91). The focus on family history
instead of genetic analysis in clinical assessment is a reasonable
approach given this genetic complexity (73, 92). Until further
studies have given utterly information, genetic tests involving
inflammatory mediators should not be part of routine clinical
practice (92).
Several case-control studies and selected animal studies
clearly demonstrate the role of the inflammatory response in
VTE (Tables 1–3). Despite this, few inflammatory mediators
have shown utility in diagnostics compared with traditional
biomarkers; D-dimer and CRP being the most important ones.
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TABLE 3 | Matrix metalloproteases as predisposing factors, diagnostic markers and prognostic markers in venous thrombosis.
Predisposing factor Acute reaction and diagnostic use Effect on thrombus resolution
MMP-9 1,562C > T ↑ SNP: 130 DVT+ and 190 DVT−
(cancer patients) vs. 215 controls (39)
↑ in VTE (80) ↑ IFN-γ enhances thrombus resolution in mice
through enhanced MMP-9 and VEGF
expression in mice (66)





↑ MMPs: 201 DVT vs. 60 controls (48) ↑ MMP-1/8: 47 of 201 DVT developing PTS
(48)
MMP- 2, 3, 7,
8, 9
↑21 DVT vs. 20 controls, ↔21 DVT vs. 68 non-DVT
(69)
This table summarizes selected key human and animal studies of MMP response in venous thrombosis. Arrows indicate the following: the MMP/genetic polymorphism coding for the
cytokine is elevated/more frequent (↑), decreased/less frequent (↓), or unchanged (↔) in DVT cohorts as a predisposing factor (left column), as part of the acute reaction (middle
column), or as a risk factor for post-thrombotic syndrome or recurrent DVT (right column). PTS, post thrombotic syndrome; SNP, single nucleotide polymorphism; TIMP, tissue inhibitor
of metalloproteases. Control, healthy control
The only inflammatory marker shown almost as helpful as D-
dimer in diagnostic work up is sP-selectin, although has so far
not proven to add definitive diagnostic value. As prognostic
factors, the studies presented in Tables 1–3 are indicating higher
inflammatory mediator levels can be used to identify patients
of risk of PTS. Larger thrombotic burden is a reasonable
explanation of these finding.
The intertwined effect of inflammation and coagulation is
an important aspect of treatment of VTE. Inflammation as a
target is responsible for parts of the effects of low molecular
heparin as it is reducing TNF-α expression (93). Furthermore,
statins have anti-inflammatory effects believed to be favourable
for thrombosis resolution (94–97). Other modulations of the
inflammatory response are explored in animal models as
possible treatments. Increased levels of cytokines such as IL-
8, CCL2 are favourable for thrombus resolution (98, 99), and
impaired inflammatory response by cytokine receptor deletion or
neutropenia also reduces thrombus resolution (100, 101). This
leads to the assumption that the inflammatory response is a
prerequisite not only for the thrombus formation, but also the
resolution, although the results from using cytokine stimulation
are conflicting (102). However, the resolution is also dependent
on the leukocytes as neutropenia seems to reduce the capability
for thrombus resolution (87).
Future research, both basic laboratory research including
studies in murine models, in addition to translational and
clinical research, are important to completely bridging the
association between inflammation and VTE. This includes a
better understanding of the inflammatory aspects of thrombosis
and the pathophysiology role of mediator molecules, herein
their potential role as diagnostic and prognostic biomarkers.
The later will be of special interest for selective patient
groups, there biomarkers have demonstrated to be of limited
values, including patients with malignant disease and patients
with other inflammatory comorbidities. Until then, good
clinical judgments combined with established biomarkers and
radiological examinations, are still the basic tools in diagnostic
approaches for patients with VTE.
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